LONDON – The UK biopharmaceutical industry is preparing a new defense against the incursions that health technology assessments (HTA) are making on its ability to get reimbursement for some drugs and the full price for others, turning to real-world data to demonstrate the value of its products. (BioWorld International) Read More
